Enzalutamide (Xtandi®) on or after chemotherapy

Assessment Status Assessment process complete
Drug Enzalutamide
Brand Xtandi®
Indication For the treatment of adult men with metastatic castration-resistant prostate cancer (mCRPC) whose disease has progressed on or after docetaxel therapy.
Assessment Process
Rapid review commissioned 28/06/2013
Rapid review completed 10/07/2013
Rapid review outcome Full Pharmacoeconomic Evaluation Recommended
Full submission received from Applicant 06/12/2013
NCPE assessment completed 10/04/2014
NCPE assessment outcome Reimbursement not Recommended

In October 2013, Astellas Pharma Co Ltd submitted an economic evaluation on the cost effectiveness of enzalutamide for this indication.  An updated dossier was submitted on the 6th December 2013.

The NCPE believe that, at the submitted price, enzalutamide is not cost effective for the treatment of adults with metastatic castration-resistant cancer whose disease has progressed on or after docetaxel.

Technical Summary

August 2014

The HSE has approved reimbursement following confidential price negotiations.